Indian Alliance For Pfizer/BioNTech’s COVID-19 Vaccine?
COVAX Supplies Being Discussed
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.
You may also be interested in...
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
Indian regulator is likely to ask Pfizer/BioNTech to conduct clinical trials before granting an accelerated approval, but recruitment could prove challenging for the COVID-19 vaccine as anaphylactic reactions in the US and UK sparks worry.
Pfizer and separately Serum Institute, which is partnering Oxford/AstraZeneca's COVID-19 candidate, have filed for emergency use authorizations of their vaccines in India. While Pfizer is yet to conduct clinical trials in India, questions over a serious adverse event during Serum's trials linger despite the regulator's clean chit.